

1 **Trikafta therapy alters the CF lung mucus metabolome reshaping microbiome niche space**

2

3 Lauren M. Sosinski¹, Christian Martin H.¹, Kerri A. Neugebauer¹, Lydia-Ann J. Ghuneim¹, Douglas V.
4 Guzior^{1,2}, Alicia Castillo-Bahena³, Jenna Mielke⁴, Ryan Thomas⁵, Marc McClelland³, Doug Conrad⁴ and
5 Robert A. Quinn^{1*}

6

7 ¹Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA.

8 ²Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI,
9 USA.

10 ³Spectrum Health, Grand Rapids, MI, USA

11 ⁴Department of Medicine, University of California San Diego, La Jolla, CA

12 ⁵Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA

13

14 * To whom the correspondence should be addressed: Robert Quinn. Department of Biochemistry and
15 Molecular Biology, Michigan State University, East Lansing, Michigan, USA. Email:

16 quinnrob@msu.edu

17

18 Author contributions: LS, CMH, KN, LJG, DVG generated data; LS, CMH, KN and RAQ analyzed data,
19 ACB, JM collected samples; MM, RT and DC recruited patients; LM, CMH, KN, and RAQ wrote the
20 paper; RAQ obtained funding for the project

21

22 Sources of support: NIH R01AI145925

23 Running head: TRIKAFTA Microbiome and Metabolome Dynamics in CF

24

25

26

27

28

29

30 **Abstract**

31 **Background:** Novel small molecule therapies for cystic fibrosis (CF) are showing promising efficacy
32 and becoming more widely available since recent FDA approval. The newest of these is a triple therapy
33 of Elexacaftor-Tezacaftor-Ivacaftor (ETI, Trikafta®). Little is known about how these drugs will affect
34 polymicrobial lung infections, which are the leading cause of morbidity and mortality among people with
35 CF (pwCF).

36 **Methods:** we analyzed the sputum microbiome and metabolome from pwCF (n=24) before and after
37 ETI therapy using 16S rRNA gene amplicon sequencing and untargeted metabolomics.

38 **Results:** The lung microbiome diversity, particularly its evenness, was increased ($p = 0.044$) and the
39 microbiome profiles were different between individuals before and after therapy (PERMANOVA $F=1.92$,
40 $p=0.044$). Despite these changes, the microbiomes were more similar within an individual than across
41 the sampled population. There were no specific microbial taxa that were different in abundance before
42 and after therapy, but collectively, the log-ratio of anaerobes to classic CF pathogens significantly
43 decreased. The sputum metabolome also showed changes due to ETI. Beta-diversity increased after
44 therapy (PERMANOVA $F=4.22$, $p=0.022$) and was characterized by greater variation across subjects
45 while on treatment. This significant difference in the metabolome was driven by a decrease in peptides,
46 amino acids, and metabolites from the kynurenine pathway. Metabolism of the three small molecules
47 that make up ETI was extensive, including previously uncharacterized structural modifications.

48 **Conclusions:** This study shows that ETI therapy affects both the microbiome and metabolome of
49 airway mucus. This effect was stronger on sputum biochemistry, which may reflect changing niche
50 spaces for microbial residency in lung mucus as the drug's effects take hold, which then leads to
51 changing microbiology.

52 **Funding:** This project was funded by a National Institute of Allergy and Infectious Disease Grant
53 R01AI145925

54 **Keywords:** Cystic Fibrosis, sputum, microbiome, metabolome, Trikafta

55

56 Introduction

57 Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the cystic fibrosis
58 transmembrane conductance regulator (CFTR) gene. CFTR is a cAMP-regulated ion channel used for
59 the transport anions across epithelial cells (1). Mutations in this gene cause a thickening of mucosal
60 secretions, primarily in the respiratory and gastrointestinal systems, and chronic polymicrobial infection
61 of the airways (1). Common clinical representations of this disease include, but are not limited to,
62 increased polymicrobial infections, infertility, decreased lung function, and pancreatic insufficiency (1).
63 Pancreatic sufficiency is inherently linked to the specific mutation class, but other aspects of CF
64 pathology have unclear links to genotype (2, 3). It is clear however, that those with severe disease,
65 especially the delF508 mutation, are plagued by chronic lung infection throughout their lifetime (4).

66 The lung microbiome of people with CF (pwCF) has been well characterized and includes
67 bacteria, viruses, and fungi (5–7). Studies of sputum expectorated from the airways have demonstrated
68 that the CF lung microbiome diversity decreases as the disease progresses over time, becoming
69 dominated by opportunistic pathogens, such as *Pseudomonas aeruginosa* (4, 8). Thickened mucus
70 within the lungs allows for these pathogens to form a biofilm and thrive (9). The chemical composition
71 of this matrix has been shown to mainly include DNA, amino acids, peptides, antibiotics, inflammatory
72 lipids, and a myriad of small molecules from host, microbial, and xenobiotic sources (10–14).

73 In November 2019, a new triple therapy drug Elexacaftor-Tezacaftor-Ivacaftor (ETI, Trikafta®)
74 was approved by the United States Food and Drug Administration (FDA) for the treatment of CF (15).
75 ETI is composed of three different compounds: Tezacaftor, Elexacaftor, and Ivacaftor (16). People with
76 at least one copy of the F508del mutation, which is the most common mutation across CF patients, are
77 eligible to take ETI. Studies from clinical trials and data available since approval have shown that the
78 treatment is providing remarkable improvements in lung function and other disease symptoms (17, 18).
79 Little is known, however, about how this new therapy will affect the CF lung microbiome and
80 metabolome.

81 In this study, sputum samples from pwCF (n=24) were collected before and after therapy (within
82 one year of FDA approval) and analyzed using an integrated multi-omics approach including 16S rRNA
83 amplicon sequencing and LC-MS/MS untargeted metabolomics. Changes in both microbiome and
84 metabolome were identified and indicate a significant shift in the niche space of airway mucus and its
85 microbial occupancy from ETI therapy.

86 Methods

87 Further detail available in supplemental methods.

88 **Sample Collection.** Sputum samples were collected during routine clinical visits from adult pwCF (>18
89 years) at two separate CF clinics (patient details table S1). Samples were obtained from the most
90 recent clinical visit prior to ETI administration and the most recent visit after ETI administration if
91 sputum production was possible. Ethical approval for the collections at the University of California San
92 Diego adult CF clinic was obtained from the UCSD Human Research Protections Program Institutional
93 Review Board under protocol #160078. Institutional review board approval was also provided for the
94 collections at the Spectrum Health adult CF clinic in Grand Rapids, MI by the Spectrum Health Human
95 Research Protection Program Office of the Institutional Review Board under IRB #2018-438.

96 **DNA Extraction, qPCR, and 16S rRNA single amplicon sequencing.** A Qiagen® PowerSoil® DNA
97 extraction kit was used to extract DNA from the sputum samples following standard protocol. PCR
98 amplification was then performed using 27F and 1492R primers targeting the bacterial 16S rRNA gene
99 to test for DNA amplification quality. Bacterial 16S rRNA V4 amplicon sequencing was performed with
100 primers 515f/806r on an Illumina® MiSeq® at the Michigan State University Sequencing Core. The raw
101 sequences were processed using QIITA (qiita.ucsd.edu) (19), which is driven by QIIME2 algorithms
102 (20), and quality filtered to generate amplicon sequence variants (ASVs) through the deblur method
103 (21). ASVs in the microbiome data were classified as ‘classic CF pathogens’ or ‘anaerobes’ based on
104 the methods of Raghuvanshi *et al.* (2020) and Carmody *et al.* (2018) (22, 23). The specific ASVs and
105 their classifications are available in table S2. qPCR was executed using universal 16S primers (43) and
106 Applied Biosystems SYBR Green PCR Master Mix with three technical replicates were obtained for
107 each sample. The microbiome data is publicly available at the Qiita repository under study #13507.

108
109 **Metabolomics.** Organic metabolite extraction was performed by adding twice the sample volume of
110 chilled 100% methanol, vortexing briefly, and incubating at room temperature for 2 hours. Samples
111 were then centrifuged at 10,000 x g and the supernatant was collected. Methanolic extracts were
112 analyzed on a Thermo Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometer coupled to a
113 Vanquish ultra-high-performance liquid chromatography system. All raw files were converted to
114 .mzXML format and then processed with MZmine 2.53 software (24), GNPS molecular networking (25)
115 and SIRIUS (26). MZmine 2 parameters are available in the supplementary information (Table S3). The
116 network job is available at
117 <https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=c700397169ff447490f764c34abb5abd> and the
118 mass spectrometry data were deposited on public repository massive.ucsd.edu under MassIVE ID
119 [MSV000087364](https://massive.ucsd.edu/MSV000087364).

120

121 **Statistical Analysis.** Statistical approaches for both the microbiome and metabolome data were
122 similar, due to the inherent structural similarity of the multivariate data sets. Normality of the different
123 quantitative measures was first tested using a Shapiro-Wilk (SW) test in order to determine appropriate
124 statistical methods. If the data was normally distributed, a paired dependent means t-test (DM t-test)
125 was used. Otherwise, a Wilcoxon signed-rank test (WSRT) was used. Alpha-diversity was calculated
126 for both datasets using the Shannon index. Beta-diversity measures were calculated using the
127 weighted UniFrac distance for the microbiome and Bray-Curtis distance for the metabolome. Beta-
128 diversity was visualized for both datasets using principal coordinates analysis (PCoA) and the EMPeror
129 software (27). Beta-diversity clustering significance pre- and post-ETI were tested using a
130 Permutational Multivariate Analysis of Variance (PERMANOVA) method with 999 permutations. Cross
131 population beta-diversity comparisons were done between pwCF before ETI therapy, after therapy,
132 across the whole dataset, and within individuals pre- and post-therapy.

133 To identify metabolite and microbial drivers of the difference pre- and post-therapy, a random
134 forest (RF) machine learning approach was used via the randomForest package in R (28). The top 50
135 variables of importance were further explored. As all individual metabolite and microbiome abundance
136 data were not considered normally distributed, statistical significance for individual microbial and
137 metabolite changes before and after ETI treatment were calculated using the WRST. The p-values
138 were adjusted for multiple comparisons using the Benjamini-Hochberg method.

139 Microbe and metabolite association vectors were calculated using mmvec (29). Detail of the
140 mmvec parameters and analysis is available in the online supplement.

141

142 **Results**

143

144 **Microbiome and Metabolome Diversity Changes from ETI Treatment.** Shannon diversity and
145 number of ASVs of the microbiome showed an increase between samples collected before and after
146 ETI treatment, but this did not reach statistical significance (Shannon SW normality $p=0.238$, WSRT
147 $p=0.062$; Number of ASVs SW normality $p=0.0043$, DM t-test $p=0.12$, Fig. 1a). The Pielou evenness,
148 however, was significantly higher post-therapy than before ETI (SW normality $p=0.074$, WSRT
149 $p=0.044$). The metabolome did not show a significant change in Shannon index after ETI therapy (SW
150 $p=0.0017$, DM t-test, $p=0.45$, Fig. 1b) or evenness (Pielou evenness SW $p=0.13$, DM t-test $p=0.30$).
151 However, the number of molecular features did decrease after therapy (SW $p=0.0027$ DM t-test
152 $p=0.010$). Collectively, this alpha-diversity analysis demonstrates that new ASVs were not being
153 introduced into the sputum microbiome, but rather became more even with previously present taxa. In

154 regard to the alpha-diversity of the metabolome, there was a decrease in the total number of
155 metabolites present.

156 PCoA plots were used to visualize beta-diversity differences between samples of the two data
157 types (Fig. 1c, d). In both the microbiome and metabolome, there was a cluster of more similar samples
158 and a spread along the first and second axis indicating samples with greater diversity. PERMANOVA
159 testing showed that the microbiome profile of the sputum samples changed after ETI treatment
160 ($p=0.044$). The metabolome profile also changed significantly after treatment ($p=0.002$), with a stronger
161 metric of difference in the metabolome compared to the microbiome (F-value=1.92 microbiome, F-
162 value=3.12 metabolome, Fig. 1c, d). There was statistically significant movement along the first
163 principal coordinate axis after ETI therapy for both the microbiome (SW test $p=0.02$, DM t-test
164 $p=0.0027$) and the metabolome (SW $p=0.0011$, DM t-test $p=0.00071$) indicating that changes in these
165 measures occurred similarly within this beta-diversity space. There was no significant change along the
166 second axis. The beta-diversity differences among samples were also compared before, between, and
167 after ETI treatment across subjects and within subjects (SW normality on beta-diversity distributions
168 microbiome $p=1.4 \times 10^{-15}$, metabolome $p=2.2 \times 10^{-16}$). The microbiome showed the smallest change
169 within subjects before and after therapy than across subjects at any period, indicating that although the
170 microbiome profiles change significantly (Fig. 1e), there was still more similarity within an individual
171 before and after therapy than across the population no matter the treatment category. The metabolome
172 beta-diversity comparisons showed different trends than the microbiome. The largest beta-diversity in
173 metabolite profiles was seen across patients in samples collected after therapy, signifying that the
174 chemical makeup of sputum becomes far more varied across people once administered ETI (Fig. 1f). In
175 contrast, the metabolomes were the most similar across subjects prior to ETI therapy, indicating that
176 sputum metabolite profiles were relatively similar prior to ETI administration, but varied greatly across
177 individuals after treatment.

178

179 **Microbial Changes After ETI Treatment.** A random forest classification was used to determine how
180 well the microbiome data reflected the pre- or post-treatment groups and to rank the ASVs by their
181 contribution to that classification. Overall, the random forest model poorly classified the microbiome
182 data with an error rate of 44.7%. *Veillonella parvula* and *Staphylococcus* sp. were ASVs with strong
183 classifiers (Table S4) with a high overall abundance. However, none of the ranked ASVs were
184 significantly different between pre- and post-treatment samples after correction for false-discovery
185 (Benjamini-Hochberg corrected, WSRT $p>0.05$). The ASV representing *Pseudomonas* showed
186 dynamic changes in some individuals, but it was not significantly different in the overall paired data (Fig.
187 2). Similarly, at the family level, there was no significant difference before and after therapy following

188 false discovery rate correction. We also summed the abundance of all 'CF pathogens' and 'anaerobes'
189 (as described in table S2) and compared the log-ratio of pathogens/anaerobes, as described by
190 Raghuvanshi *et al.* (2020) (22), and found it significantly decreased following ETI therapy (SW $p =$
191 0.233, WSRT $p = 0.013$, Fig. 2).

192 A qPCR assay using universal primers for the bacterial 16S rRNA gene (43) was used to
193 calculate the total number of rRNA copies/mL of sputum pre- and post-therapy. The mean prior to
194 therapy was 1.17×10^9 copies/mL and after therapy was 7.62×10^8 copies/mL. This difference was not
195 statistically significant but did show a decreasing trend (SW $p = 0.0027$, DM t-test $p = 0.061$, Fig. 2).

196

197 **Metabolite Changes After ETI Treatment.** Annotated metabolites were first grouped into molecular
198 families and summed to determine overall changes. This analysis showed the major metabolomic
199 signature due to ETI therapy was a decrease in peptides and amino acids. Though phosphocholine and
200 phosphoethanolamine abundance did not change before and after ETI, peptide and amino acid
201 abundance significantly decreased (Fig. 3a). This demonstrates an overall change in the relative
202 abundance of this compound class, while other classes remained static.

203 A random forest machine learning classification was used to assess how well the complete
204 metabolomic data reflected changes after ETI therapy. The out-of-bag error rate of the classification
205 was 22.92% indicating that there was a metabolomic signal for ETI therapy, but not all samples were
206 correctly classified as pre- or post-treatment. The importance of each metabolite in the construction of
207 the random forest model was produced, noting the impact of each metabolite on differentiating pre- and
208 post-treatment groups (Table S5). Of the 50 most important classifiers, 13 were annotated in the GNPS
209 database and of those, 10 were annotated as amino acids or peptides. These were primarily
210 dipeptides, including Phe-Glu, Ile-Leu, Glu-Val, and Ser-Phe, as well as the amino acid tryptophan; all
211 of which significantly decreased after ETI therapy (Fig 1b). Molecular network analysis (Fig. 3c) showed
212 a diverse set of peptides that were more abundant prior to ETI therapy. Metabolites from the
213 kynurenine pathway (which includes tryptophan) were also identified as strong classifiers in the model.
214 Kynurenine, formylkynurenine, and indole abundance significantly decreased after ETI therapy (Fig.
215 3b). The *P. aeruginosa* siderophore pyochelin was detected in only 10 of the 24 patients. Comparing
216 pyochelin abundance within those 10 individuals showed that it significantly decreased after ETI
217 therapy as well (Fig. 3b). Though commonly detected in CF sputum with the metabolomics methods
218 used here, other *P. aeruginosa* specialized metabolites were not detected in this study, except for one
219 quinolone (NHQ) that was detected in 6 samples.

220

221 **Trikafta Metabolism in CF Mucus.** ETI is a triple therapy of the compounds Ivacaftor, Elexacaftor, and
222 Tezacaftor. All three drugs were identified in the sputum metabolome by MS/MS analysis with similar
223 fragmentation behavior to that described by Reyes-Ortega *et al.* (2020) (30). This included the known
224 and unknown metabolized products of the parent drugs with related MS/MS spectra (Fig. 4). Ivacaftor
225 had extensive metabolism revealed by molecular networking with the parent drug having six related
226 nodes with unique retention times. Two of these are known, M1 and M6, as hydroxymethyl ivacaftor
227 and ivacaftor carboxylate, respectively. Other modifications of the compounds were also seen,
228 including further hydroxylations and carboxylations. Tezacaftor metabolism was also identified. This
229 included dehydrogenation (metabolite M1, m/z 519.1400, $C_{26}H_{26}F_3N_2O_6+H^+$). Also detected, but not
230 shown, was a phosphorylated metabolite (m/z 599.1401, $C_{26}H_{27}F_3N_2O_9P+H^+$) and a known glucuronate
231 (metabolite M3, Fig. 4a). Elexacaftor exhibited only one metabolic transformation – the loss of a methyl
232 group on its pyrazole ring (Fig. 4).

233 Ivacaftor and Tezacaftor were detected in sputum samples both prior to and after ETI
234 administration. These two compounds were released as therapies in prior formulations of CFTR
235 correctors, likely explaining their presence. Elexacaftor, the next generation corrector unique to ETI,
236 was present in sputum after its prescription as expected. However, one subject unexpectedly had
237 Elexacaftor present in their lung sputum prior to clinical knowledge of administration of ETI. The
238 presence of Ivacaftor and Tezacaftor in the sputum of pwCF prior to administration of ETI led to the
239 investigation of whether or not the presence of previously approved correctors/potentiators in sputum
240 prior to administration of ETI may have buffered the microbiome dynamics observed. Ivacaftor (a
241 component of Kalydeco®, Orkambi®, and Symdeko®) was found in 11 of the 24 patients prior to ETI
242 therapy. There was no significant difference in the alpha or beta-diversity changes between subjects
243 that had Ivacaftor in their sputum prior to ETI and those that did not ($p>0.05$, Fig. S1). This indicates
244 that prior CFTR corrector/potentiator therapy was not contributing significantly to the overall changes
245 seen with ETI in this study, allowing these changes to be definitively attributed to this specific triple
246 therapy

247
248 **Microbiome/Metabolite Associations Through ETI Therapy.** To associate microbiome and
249 metabolome dynamics across the dataset, we employed mmvec. This is a novel algorithm robust to the
250 challenges of compositionality of omics datasets that calculates conditional probabilities of the
251 association between all ASVs in the microbiome data with all metabolite features. The overall neural
252 network showed a strong association between a changing microbiome and metabolome (Fig. S2).
253 Additionally, the biplot of the mmvec algorithm enabled visualization of the microbiome vectors
254 associated with the metabolomic space. In the biplot, a clear separation in vector directionality was

255 found between pathogen and anaerobe associations with the metabolome. This indicates that the
256 metabolites that change in association pathogens are not the same metabolites that associate with
257 changing anaerobes. Drivers of the metabolite changes associated with pathogens were mostly
258 peptides (Fig. 5a); those same peptides shown to be decreasing after ETI therapy. Plotting the
259 conditional probabilities of each peptide with the mean of all pathogens and all anaerobes in the
260 dataset showed that the peptides were significantly associated with pathogens (WSRT $p < 0.001$) (Fig.
261 5b). Kynurenine, another metabolite found to decrease with ETI therapy, was most strongly associated
262 with pathogens. This analysis indicates the decrease of peptides and kynurenine in sputum samples
263 collected from pwCF is associated with a decrease in the relative abundance of pathogens (Fig. 5c).

264 Discussion

265 This study assessed the multi-omic changes in sputum from pwCF after administration of the
266 novel CF triple therapy ETI. This promising new therapy has shown significant improvement in lung
267 function and symptom measures of pwCF in clinical trials with great potential to improve the lives of
268 these individuals (15, 16). Improving CFTR function is a major goal of ETI therapy as it is the underlying
269 cause of CF. However, many adult patients have been living with persistent lung infections and an
270 evolving microbiome for decades. Promising as the treatment is, it is mostly unknown how the therapy
271 will affect lung infections and the chemistry of sputum. This is of paramount importance; if the microbial
272 infections in the lungs of pwCF do not clear and/or change favorably, then the full benefits of the
273 therapy may not be realized. Preliminary studies of other CFTR modulators and correctors, specifically
274 Ivacaftor which has received the most attention due to having the earliest FDA approval, have shown
275 some changes in microbial diversity measures with treatment (31), specifically in the gut (32, 33), but
276 most studies find little change in the airway microbiome (33–36). The addition of CFTR correctors, such
277 as Lumacaftor, have shown an increase in microbial diversity in the CF airways (37), but other studies
278 also show less marked responses (38). This study, to our knowledge, is the first to look specifically at
279 the microbiome and metabolome changes resulting from ETI therapy (which includes the new highly
280 effective potentiator Elexacaftor). Effects of the treatment were seen in both the microbiome and the
281 metabolome. By beta-diversity measures, the effect was stronger in the metabolome, demonstrating
282 that the drugs were altering the biochemical environment of CF mucus.

283 Microbial diversity increased with ETI therapy, indicating that the microbiome in the lungs of
284 pwCF is becoming more complex. This increase was driven by a higher microbial evenness, a metric
285 that contributes to the Shannon diversity, though the Shannon index itself did not reach statistical
286 significance. Therefore, the lung microbiome of pwCF was not necessarily gaining new or losing old
287 microbial members after ETI therapy, but those present became more similar in their relative

288 abundances, possibly an indication of greater community stability. The overall profiles of the
289 microbiome were significantly changed after ETI therapy and did so in a similar way, as shown by the
290 homogeneous directional movement across the first principal component axis. Despite these overall
291 changes, there was no single organisms that significantly altered from ETI therapy after multiple-
292 comparisons correction. This is likely due to the widely known personalization in the CF microbiome (8,
293 39). Individuals have very different microbial profiles, so the start and endpoints from any
294 pharmaceutical treatment may not be universal across subjects. This personalization was again
295 observed here; subjects were still more similar to themselves after ETI therapy than to other subjects. A
296 larger sample size in this study may have reached statistical significance for microbial taxa of interest
297 because the trends for pathogens, such as *P. aeruginosa* and *Staphylococcus*, were showing strong
298 reductions in abundance, while anaerobes were showing an increase. Accordingly, a collective
299 comparison of the decrease in the log-ratio of the pathogen:anaerobe abundances did reach statistical
300 significance. This finding validates this approach of simplifying the microbiome to these two
301 communities and indicates that there is an overall reduction in the relative abundance of collective
302 clinical pathogens, even though not all patients have the same pathogen. There was also a trend in the
303 decreased bacterial load after ETI therapy, supporting that the increase in diversity seen from
304 microbiome measures may be associated with a decrease in total bacterial load from expectorated
305 sputum, though this too did not reach statistical significance. In summary, ETI therapy significantly
306 altered the lung microbiome, exemplified as an increased microbial evenness driven by a reduction in
307 the relative abundance of pathogens in place of an increase in the relative abundance of anaerobes.
308 This increase in anaerobes may have clinical relevance for treating lung infections in the new era of
309 highly effective CFTR modulators. The role of anaerobes within the CF lung is rather unclear as they
310 are associated with better lung function (40), but also pulmonary exacerbations (22, 23, 41). In light of
311 these findings, antibiotic treatment with more anaerobic coverage may be an effective approach to treat
312 CF infections in those prescribed ETI.

313 The metabolome showed significant changes following ETI therapy, with stronger metrics than
314 the microbiome. This was characterized by an increase in variability across subjects. Lung sputum
315 metabolomes were relatively similar prior to ETI therapy, but, when on drug, the sputum metabolomes
316 were highly diverse across subjects. These interesting chemical dynamics indicate that ETI induces a
317 sort of metabolomic turmoil within the airways of pwCF, where the lung sputum biochemistry changes
318 significantly with a highly varied outcome across individuals. However, similar to changes in the
319 microbiome, the directionality of change was uniform, indicating a common metabolomic shift driven by
320 ETI. Despite this variability, there were some uniform changes identified, particularly changes in
321 peptides, amino acids, and kynurenine metabolism. The latter was identified as an important pathway

322 associated with *P. aeruginosa* dynamics from Lumacaftor/Ivacaftor therapy in a previous study (38),
323 which the findings here and may be a universal consequence of CFTR modulator treatment. The
324 decrease in the overall abundance of peptides, particularly dipeptides, links these metabolites to a
325 previous study that associated them with worsening lung function (13). These peptides were shown to
326 be sourced from neutrophil elastase activity. Thus, the decrease in these metabolites with ETI therapy
327 may also represent a reduction in this inflammatory process, though inflammatory markers were not
328 measured in this study. There may be a link between the decrease in kynurenine metabolism and
329 amino acids/peptides, as it is a principal pathway for the metabolism of tryptophan in humans and
330 bacteria. The reduction of peptides in sputum may reduce their availability for pathogens, particularly *P.*
331 *aeruginosa*, to metabolize through the kynurenine pathway or others. The association of kynurenine
332 metabolism with *P. aeruginosa* in a previous CFTR modulator study supports the hypothesis that this
333 therapeutic approach may reduce these compounds and reshape the carbon source available to the
334 pathogen.

335 Microbial metabolite vector associations further supported the changing relationship between
336 peptides, kynurenine metabolism, and pathogens. This approach, robust to the statistical challenges of
337 cross-omics comparisons from compositional datasets (29, 42) in addition to identifying microbiome
338 and metabolome changes, showed that the decrease in peptides and kynurenine was associated with a
339 reduction in pathogens. In light of this finding, we propose the hypothesis that ETI therapy, and possibly
340 other CFTR modulators, reshape CF microbiome niche space by reducing peptide and amino acid
341 availability. This shift may squeeze out pathogens, which are known to preferentially metabolize amino
342 acids in CF mucus (43–46).

343 Metabolomics of complex clinical samples often identifies xenobiotics such as drugs
344 administered to patients (14). Prior CFTR modulators were detected in the clinical samples from pwCF
345 in this study, including evidence of diverse metabolism of these drugs, particularly ivacaftor. This
346 created a unique opportunity to determine whether or not the presence of a previously approved CFTR
347 modulator therapy in a patient's sputum affected the microbiome and metabolome dynamics of ETI.
348 Interestingly, there was no difference in the microbial and metabolite dynamics described between
349 those taking CFTR modulators and those not. This is evidence the significant changes described in this
350 study were driven by ETI, perhaps Elexacftor itself, which is known to be a highly effective CFTR
351 potentiator. These results show promise that ETI therapy may have a particularly strong effect on the
352 CF sputum microbiome and metabolome where other CFTR modulators have not (33–36).

353 There are several caveats to our study, perhaps most importantly, ETI therapy is known to
354 reduce sputum production in pwCF. It is difficult to discern if the changes we identified here are due to
355 sputum chemical and microbial dynamics or a change in the ability to produce sputum when on CFTR

356 modulators. Instructions for expectoration were not varied before and after ETI to normalize the
357 sampling approach and all subjects in this study were able to produce sputum for collection both prior
358 to and during ETI therapy. Furthermore, the relatively small sample size may have masked some
359 specific changes, particularly with individual microbial ASVs. Larger studies of pwCF before and after
360 ETI therapy are warranted, though with the wide availability of these CFTR modulators currently makes
361 collecting ETI naïve sample difficult. Harvesting sputum samples for CF biobanks could be an effective
362 alternative. Finally, as with all untargeted metabolomics methods, a single protocol for metabolite
363 extraction and mass spectrometry analysis identifies only a fraction of the total metabolite pool. Future
364 studies on the metabolome of CF sputum in response to ETI therapy with more varied protocols may
365 reveal other important pathways that are altered by these drugs.

366 This study shows that the highly effective CF triple therapy ETI induces significant changes in
367 the CF sputum microbiome and metabolome. This is exemplified by an overall reduction in pathogens
368 compared to anaerobes in addition to reduced amino acid availability and kynurenine metabolism with
369 therapy. This shows promise for the future of CF infection therapeutics because if pathogens are
370 decreasing in abundance in place of anaerobes, antimicrobial therapy can be targeted to these
371 organisms that may have less intrinsic resistance than notorious pathogens, such as *P. aeruginosa* and
372 *S. aureus*.

373
374 **Acknowledgements:** The authors would like to thank the Spectrum Health and UC San Diego clinical
375 teams who assisted with sample and metadata collection for this study. We would like to acknowledge
376 funding from the National Institutes of Allergy and Infectious Diseases under R01 grant R01AI145925
377 awarded to PI Quinn.

378

379 **References**

- 380 1. J. C. Davies, E. W. F. W. Alton, A. Bush, Cystic fibrosis, *BMJ* **335**, 1255–1259 (2007).
- 381 2. J. Zielenski, Genotype and Phenotype in Cystic Fibrosis, *Respiration* **67**, 117–133 (2000).
- 382 3. R. K. Rowntree, A. Harris, The phenotypic consequences of CFTR mutations., *Ann. Hum. Genet.* **67**,
383 471–85 (2003).
- 384 4. B. Coburn, P. W. Wang, J. Diaz Caballero, S. T. Clark, V. Brahma, S. Donaldson, Y. Zhang, A.
385 Surendra, Y. Gong, D. Elizabeth Tullis, Y. C. W. Yau, V. J. Waters, D. M. Hwang, D. S. Guttman, Lung
386 microbiota across age and disease stage in cystic fibrosis, *Sci. Rep.* **5**, 10241 (2015).
- 387 5. L. Delhaes, S. Monchy, E. Fréalle, C. Hubans, J. Salleron, S. Leroy, A. Prevotat, F. Wallet, B.
388 Wallaert, E. Dei-Cas, T. Sime-Ngando, M. Chabé, E. Viscogliosi, The airway microbiota in cystic
389 fibrosis: a complex fungal and bacterial community--implications for therapeutic management., *PLoS*

- 390 *One* **7**, e36313 (2012).
- 391 6. H. R. Rabin, M. G. Surette, The cystic fibrosis airway microbiome., *Curr. Opin. Pulm. Med.* **18**, 622–7
392 (2012).
- 393 7. Y. W. Lim, R. Schmieder, M. Haynes, D. Willner, M. Furlan, M. Youle, K. Abbott, R. Edwards, J.
394 Evangelista, D. Conrad, F. Rohwer, Metagenomics and metatranscriptomics: Windows on CF-
395 associated viral and microbial communities., *J. Cyst. Fibros.* **12**, 154–164 (2013).
- 396 8. J. Zhao, P. D. Schloss, L. M. Kalikin, L. a Carmody, B. K. Foster, J. F. Petrosino, J. D. Cavalcoli, D.
397 R. VanDevanter, S. Murray, J. Z. Li, V. B. Young, J. J. LiPuma, Decade-long bacterial community
398 dynamics in cystic fibrosis airways., *Proc. Natl. Acad. Sci. U. S. A.* **109**, 5809–14 (2012).
- 399 9. D. J. Hassett, M. D. Sutton, M. J. Schurr, A. B. Herr, C. C. Caldwell, J. O. Matu, *Pseudomonas*
400 *aeruginosa* hypoxic or anaerobic biofilm infections within cystic fibrosis airways., *Trends Microbiol.* **17**,
401 130–8 (2009).
- 402 10. R. Manzenreiter, F. Kienberger, V. Marcos, K. Schilcher, W. D. Krautgartner, A. Obermayer, M.
403 Huml, W. Stoiber, A. Hector, M. Griese, M. Hannig, M. Studnicka, L. Vitkov, D. Hartl, Ultrastructural
404 characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy., *J.*
405 *Cyst. Fibros.* **11**, 84–92 (2012).
- 406 11. D. W. Reid, N. Misso, S. Aggarwal, P. J. Thompson, E. H. Walters, Oxidative stress and lipid-
407 derived inflammatory mediators during acute exacerbations of cystic fibrosis, *Respirology* **12**, 63–69
408 (2007).
- 409 12. J. Yang, J. P. Eiserich, C. E. Cross, B. M. Morrissey, B. D. Hammock, Metabolomic profiling of
410 regulatory lipid mediators in sputum from adult cystic fibrosis patients., *Free Radic. Biol. Med.* **53**, 160–
411 71 (2012).
- 412 13. R. A. Quinn, S. Adem, R. H. Mills, W. Comstock, L. DeRight Goldasich, G. Humphrey, A. A.
413 Aksenov, A. V. Melnik, R. da Silva, G. Ackermann, N. Bandeira, D. J. Gonzalez, D. Conrad, A. J.
414 O'Donoghue, R. Knight, P. C. Dorrestein, Neutrophilic proteolysis in the cystic fibrosis lung correlates
415 with a pathogenic microbiome, *Microbiome* **7**, 23 (2019).
- 416 14. R. A. Quinn, V. V Phelan, K. L. Whiteson, N. Garg, B. A. Bailey, Y. W. Lim, D. J. Conrad, P. C.
417 Dorrestein, F. L. Rohwer, Microbial, host and xenobiotic diversity in the cystic fibrosis sputum
418 metabolome, *ISME J.* **10**, 1483–1498 (2015).
- 419 15. C. Bear, A therapy for most with cystic fibrosis, *Cell* **180**, 211 (2020).
- 420 16. K. Ridley, M. Condren, Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic
421 Fibrosis Transmembrane Conductance Regulator Modulating Therapy, *J. Pediatr. Pharmacol. Ther.* **25**,
422 192–197 (2020).
- 423 17. H. G. M. Heijerman, E. F. McKone, D. G. Downey, E. Van Braeckel, S. M. Rowe, E. Tullis, M. A.

- 424 Mall, J. J. Welter, B. W. Ramsey, C. M. McKee, G. Marigowda, S. M. Moskowitz, D. Waltz, P. R.
425 Sosnay, C. Simard, N. Ahluwalia, F. Xuan, Y. Zhang, J. L. Taylor-Cousar, K. S. McCoy, V.-445-103 T.
426 Group, Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in
427 people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3
428 trial, *Lancet (London, England)* **394**, 1940–1948 (2019).
- 429 18. P. G. Middleton, M. A. Mall, P. Dřevínek, L. C. Lands, E. F. McKone, D. Polineni, B. W. Ramsey, J.
430 L. Taylor-Cousar, E. Tullis, F. Vermeulen, G. Marigowda, C. M. McKee, S. M. Moskowitz, N. Nair, J.
431 Savage, C. Simard, S. Tian, D. Waltz, F. Xuan, S. M. Rowe, R. Jain, V.-445-102 S. Group, Elexacaftor-
432 Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele, *N. Engl. J. Med.* **381**, 1809–
433 1819 (2019).
- 434 19. A. Gonzalez, J. A. Navas-Molina, T. Kosciólek, D. McDonald, Y. Vázquez-Baeza, G. Ackermann, J.
435 DeReus, S. Janssen, A. D. Swafford, S. B. Orchanian, J. G. Sanders, J. Shorenstein, H. Holste, S.
436 Petrus, A. Robbins-Pianka, C. J. Brislawn, M. Wang, J. R. Rideout, E. Bolyen, M. Dillon, J. G.
437 Caporaso, P. C. Dorrestein, R. Knight, Qiita: rapid, web-enabled microbiome meta-analysis, *Nat.*
438 *Methods* **15**, 796–798 (2018).
- 439 20. E. Bolyen, J. R. Rideout, M. R. Dillon, N. A. Bokulich, C. Abnet, G. A. Al Ghalith, H. Alexander, E. J.
440 Alm, M. Arumugam, Y. Bai, J. E. Bisanz, K. Bittinger, A. Brejnrod, J. Colin, C. T. Brown, B. J. Callahan,
441 A. Mauricio, C. Rodríguez, J. Chase, E. Cope, R. Da Silva, P. C. Dorrestein, G. M. Douglas, C.
442 Duvall, C. F. Edwardson, M. Ernst, J. Fouquier, J. M. Gauglitz, D. L. Gibson, A. Gonzalez, G. A.
443 Huttley, S. Janssen, A. K. Jarmusch, B. D. Kaehler, K. Bin Kang, C. R. Keefe, P. Keim, S. T. Kelley, R.
444 Ley, E. Lofffield, C. Marotz, B. Martin, D. McDonald, L. J. Mciver, V. Alexey, J. L. Metcalf, S. C. Morgan,
445 J. T. Morton, A. T. Naimey, QIIME 2: Reproducible , interactive , scalable , and extensible microbiome
446 data science, *PeerJ Prepr.* (2018), doi:10.7287/peerj.preprints.27295v2.
- 447 21. A. Amir, D. McDonald, J. A. Navas-Molina, E. Kopylova, J. T. Morton, Z. Zech Xu, E. P. Kightley, L.
448 R. Thompson, E. R. Hyde, A. Gonzalez, R. Knight, Deblur Rapidly Resolves Single-Nucleotide
449 Community Sequence Patterns, *mSystems* **2** (2017) (available at
450 <http://msystems.asm.org/content/2/2/e00191-16>).
- 451 22. R. Raghuvanshi, K. Vasco, Y. Vázquez-Baeza, L. Jiang, J. T. Morton, D. Li, A. Gonzalez, L.
452 DeRight Goldasich, G. Humphrey, G. Ackermann, A. D. Swafford, D. Conrad, R. Knight, P. C.
453 Dorrestein, R. A. Quinn, N. Chia, Ed. High-Resolution Longitudinal Dynamics of the Cystic Fibrosis
454 Sputum Microbiome and Metabolome through Antibiotic Therapy, *mSystems* **5**, e00292-20 (2020).
- 455 23. L. A. Carmody, L. J. Caverly, B. K. Foster, M. A. M. Rogers, L. M. Kalikin, R. H. Simon, D. R.
456 VanDevanter, J. J. LiPuma, S. H. Chotirmall, Ed. Fluctuations in airway bacterial communities
457 associated with clinical states and disease stages in cystic fibrosis, *PLoS One* **13**, e0194060 (2018).

- 458 24. T. Pluskal, S. Castillo, A. Villar-Briones, M. Orešič, MZmine 2: Modular framework for processing,
459 visualizing, and analyzing mass spectrometry-based molecular profile data, *BMC Bioinformatics* **11**,
460 395 (2010).
- 461 25. M. Wang, J. J. Carver, V. V. Phelan, L. M. Sanchez, N. Garg, Y. Peng, D. D. Nguyen, J. Watrous,
462 C. A. Kapon, T. Luzzatto-Knaan, C. Porto, A. Bouslimani, A. V. Melnik, M. J. Meehan, W.-T. Liu, M.
463 Crüsemann, P. D. Boudreau, E. Esquenazi, M. Sandoval-Calderón, R. D. Kersten, L. A. Pace, R. A.
464 Quinn, K. R. Duncan, C.-C. Hsu, D. J. Floros, R. G. Gavilan, K. Kleigrewe, T. Northen, R. J. Dutton, D.
465 Parrot, E. E. Carlson, B. Aigle, C. F. Michelsen, L. Jelsbak, C. Sohlenkamp, P. Pevzner, A. Edlund, J.
466 McLean, J. Piel, B. T. Murphy, L. Gerwick, C.-C. Liaw, Y.-L. Yang, H.-U. Humpf, M. Maansson, R. A.
467 Keyzers, A. C. Sims, A. R. Johnson, A. M. Sidebottom, B. E. Sedio, A. Klitgaard, C. B. Larson, C. A. P.
468 Boya, D. Torres-Mendoza, D. J. Gonzalez, D. B. Silva, L. M. Marques, D. P. Demarque, E. Pociute, E.
469 C. O'Neill, E. Briand, E. J. N. Helfrich, E. A. Granatosky, E. Glukhov, F. Ryffel, H. Houson, H.
470 Mohimani, J. J. Kharbush, Y. Zeng, J. A. Vorholt, K. L. Kurita, P. Charusanti, K. L. McPhail, K. F.
471 Nielsen, L. Vuong, M. Elfeki, M. F. Traxler, N. Engene, N. Koyama, O. B. Vining, R. Baric, R. R. Silva,
472 S. J. Mascuch, S. Tomasi, S. Jenkins, V. Macherla, T. Hoffman, V. Agarwal, P. G. Williams, J. Dai, R.
473 Neupane, J. Gurr, A. M. C. Rodríguez, A. Lamsa, C. Zhang, K. Dorrestein, B. M. Duggan, J. Almaliti,
474 P.-M. Allard, P. Phapale, L.-F. Nothias, T. Alexandrov, M. Litaudon, J.-L. Wolfender, J. E. Kyle, T. O.
475 Metz, T. Peryea, D.-T. Nguyen, D. VanLeer, P. Shinn, A. Jadhav, R. Müller, K. M. Waters, W. Shi, X.
476 Liu, L. Zhang, R. Knight, P. R. Jensen, B. Ø. Palsson, K. Pogliano, R. G. Lington, M. Gutiérrez, N. P.
477 Lopes, W. H. Gerwick, B. S. Moore, P. C. Dorrestein, N. Bandeira, Sharing and community curation of
478 mass spectrometry data with Global Natural Products Social Molecular Networking, *Nat. Biotechnol.* **34**
479 (2016), doi:10.1038/nbt.3597.
- 480 26. K. Dührkop, M. Fleischauer, M. Ludwig, A. A. Aksenov, A. V. Melnik, M. Meusel, P. C. Dorrestein, J.
481 Rousu, S. Böcker, SIRIUS 4: a rapid tool for turning tandem mass spectra into metabolite structure
482 information, *Nat. Methods* **16**, 299–302 (2019).
- 483 27. Y. Vázquez-Baeza, M. Pirrung, A. Gonzalez, R. Knight, EMPERor: a tool for visualizing high-
484 throughput microbial community data., *Gigascience* **2**, 16 (2013).
- 485 28. L. Breiman, Random Forests, *Mach. Learn.* **45**, 5–32 (2001).
- 486 29. J. T. Morton, A. A. Aksenov, L. F. Nothias, J. R. Foulds, R. A. Quinn, M. H. Badri, T. L. Swenson,
487 M. W. Van Goethem, T. R. Northen, Y. Vazquez-Baeza, M. Wang, N. A. Bokulich, A. Watters, S. J.
488 Song, R. Bonneau, P. C. Dorrestein, R. Knight, Learning representations of microbe–metabolite
489 interactions, *Nat. Methods* , 1–9 (2019).
- 490 30. F. Reyes-Ortega, F. Qiu, E. K. Schneider-Futschik, Multiple Reaction Monitoring Mass
491 Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in

- 492 Cystic Fibrosis: A High-Throughput Method, *ACS Pharmacol. Transl. Sci.* **3**, 987–996 (2020).
- 493 31. N. J. Ronan, G. G. Einarsson, M. Twomey, D. Mooney, D. Mullane, M. NiChroinin, G. O'Callaghan,
494 F. Shanahan, D. M. Murphy, O. J. O'Connor, C. A. Shortt, M. M. Tunney, J. A. Eustace, M. M. Maher,
495 J. S. Elborn, B. J. Plant, CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose
496 Chest CT Scores After CFTR Modulation With Ivacaftor, *Chest* **153**, 395–403 (2018).
- 497 32. C. Y. Ooi, S. A. Syed, L. Rossi, M. Garg, B. Needham, J. Avolio, K. Young, M. G. Surette, T.
498 Gonska, Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation, *Sci.*
499 *Rep.* **8**, 17834 (2018).
- 500 33. M. I. Kristensen, K. M. de Winter-de Groot, G. Berkers, M. L. J. N. Chu, K. Arp, S. Ghijsen, H. G. M.
501 Heijerman, H. G. M. Arets, C. J. Majoor, H. M. Janssens, R. van der Meer, D. Bogaert, C. K. van der
502 Ent, Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in
503 People with CF and a S1251N Mutation., *J. Pers. Med.* **11** (2021), doi:10.3390/jpm11050350.
- 504 34. J. K. Harris, B. D. Wagner, E. T. Zemanick, C. E. Robertson, M. J. Stevens, S. L. Heltshe, S. M.
505 Rowe, S. D. Sagel, Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in
506 Patients with Cystic Fibrosis and the G551D Mutation, *Ann. Am. Thorac. Soc.* **17**, 212–220 (2019).
- 507 35. A. Y. Peleg, J. M. Choo, K. M. Langan, D. Edgeworth, D. Keating, J. Wilson, G. B. Rogers, T.
508 Kotsimbos, Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory
509 microbiota composition, *J. Cyst. Fibros.* **17**, 50–56 (2018).
- 510 36. C. Bernarde, M. Keravec, J. Mounier, S. Gouriou, G. Rault, C. Férec, G. Barbier, G. Héry-Arnaud,
511 Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a
512 G551D mutation., *PLoS One* **10**, e0124124 (2015).
- 513 37. S. Y. Graeber, S. Boutin, M. O. Wielpütz, C. Joachim, D. L. Frey, S. Wege, O. Sommerburg, H.-U.
514 Kauczor, M. Stahl, A. H. Dalpke, M. A. Mall, Effects of Lumacaftor-Ivacaftor on Lung Clearance Index,
515 Magnetic Resonance Imaging and Airway Microbiome in Phe508del Homozygous Patients with Cystic
516 Fibrosis, *Ann. Am. Thorac. Soc.* (2021), doi:10.1513/AnnalsATS.202008-1054OC.
- 517 38. A. H. Neerincx, K. Whiteson, J. L. Phan, P. Brinkman, M. I. Abdel-Aziz, E. J. M. Weersink, J.
518 Altenburg, C. J. Majoor, A. H. Maitland-van der Zee, L. D. J. Bos, Lumacaftor/ivacaftor changes the
519 lung microbiome and metabolome in cystic fibrosis patients, *ERJ Open Res.* **7**, 731–2020 (2021).
- 520 39. S. V Lynch, K. D. Bruce, The cystic fibrosis airway microbiome., *Cold Spring Harb. Perspect. Med.*
521 **3**, a009738 (2013).
- 522 40. C. Lamoureux, C.-A. Guilloux, C. Beauruelle, A. Jolivet-Gougeon, G. Héry-Arnaud, Anaerobes in
523 cystic fibrosis patients' airways, *Crit. Rev. Microbiol.* **45**, 103–117 (2019).
- 524 41. R. A. Quinn, K. Whiteson, Y.-W. Lim, P. Salamon, B. Bailey, S. Mienardi, S. E. Sanchez, D. Blake,
525 D. Conrad, F. Rohwer, A Winogradsky-based culture system shows an association between microbial

- 526 fermentation and cystic fibrosis exacerbation, *ISME J.* **9** (2015), doi:10.1038/ismej.2014.234.
- 527 42. G. B. Gloor, J. M. Macklaim, V. Pawlowsky-Glahn, J. J. Egozcue, Microbiome Datasets Are
528 Compositional: And This Is Not Optional, *Front. Microbiol.* **8**, 2224 (2017).
- 529 43. J. M. Flynn, D. Niccum, J. M. Dunitz, R. C. Hunter, Evidence and Role for Bacterial Mucin
530 Degradation in Cystic Fibrosis Airway Disease, *PLoS Pathog.* **12**, 1–21 (2016).
- 531 44. S. R. Thomas, A. Ray, M. E. Hodson, T. L. Pitt, Increased sputum amino acid concentrations and
532 auxotrophy of *Pseudomonas aeruginosa* in severe cystic fibrosis lung disease., *Thorax* **55**, 795–7
533 (2000).
- 534 45. A. L. BARTH, T. L. PITT, The high amino-acid content of sputum from cystic fibrosis patients
535 promotes growth of auxotrophic *Pseudomonas aeruginosa*, *J. Med. Microbiol.* **45**, 110–119 (1996).
- 536 46. R. A. Quinn, Y. W. Lim, H. Maughan, D. Conrad, F. Rohwer, K. L. Whiteson, Biogeochemical forces
537 shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung, *MBio* **5**
538 (2014), doi:10.1128/mBio.00956-13.

539

540 **Figure Legends.**

541

542 **Fig. 1.** *Alpha and Beta-diversity of Lung microbiomes before and after ETI.* Alpha-diversity measures of
543 a) microbiome data and b) metabolome data before (N_ETI) and after ETI therapy. P-values shown are
544 from either the DM t-test or WSRT after testing for normality. Principal coordinate analysis plots of beta-
545 diversity data for c) microbiome data with significance calculated utilizing the weighted UniFrac distance
546 and d) metabolome data with significance calculated utilizing the Bray-Curtis distance. PERMANOVA
547 statistics and the percent of variance explained by each axis are shown. Boxplots of positions on the
548 first principal coordinate are shown tested for significance with the DM t-test. Beta-diversity cross
549 comparisons within the e) microbiome and f) metabolome data. Cross comparisons were done across
550 patients before and after ETI therapy, across the entire dataset, and within subjects before and after
551 ETI therapy (within). Statistical significance was first tested with an ANOVA followed by an ad-hoc
552 Tukey's test. Shared letters denote distributions that are significantly different from each other.

553

554 **Fig. 2.** *Microbiome changes throughout ETI therapy.* a) Taxonomic dynamics at the family level of
555 ASVs in each subject before (N) and after (T) ETI therapy. b) The rRNA copies/mL of sputum, log-
556 ration of pathogen:anaerobes and ASV dynamics before and after ETI therapy.

557

558 **Fig. 3.** *Metabolite network of peptides and other metabolite changes.* a) Molecular family metabolite
559 abundance changes pre- and post-therapy. b) Individual metabolite changes pre- and post-therapy. c)






560 Molecular network of peptides identified by GNPS library searching. Each node represents a unique
561 MS/MS spectrum (putative metabolite), connections between the nodes are determined and width-
562 scaled by the cosine score from MS/MS alignment. Pie charts are the total feature abundance colored
563 according to the legend.



564





565 **Fig. 4.** *ETI metabolism detected in sputum metabolomic data.* a) Three separate molecular networks
566 are shown for Ivacaftor, Tezacaftor, or Elexacaftor and their related metabolic products as identified by
567 MS/MS spectral alignments. Each node in a network represents a unique MS/MS spectrum and
568 connections between the nodes indicate spectral similarity as identified by the cosine score. The width
569 of the edges are scaled to the cosine score and the pie chart inside nodes represent the sum of the
570 area-under-curve abundance of that molecule in either pre- (red) or post-treatment (blue) sputum
571 samples. The nodes are highlighted by whether they represent parent drug, known metabolized
572 product, or putative unknown metabolized product. Putative structures of the metabolites are shown
573 with their molecular formulas, retention times, and exact masses. Note that the stereochemistry of
574 some of the metabolized products cannot be discerned with this level of MS/MS annotation. b) Boxplots
575 of the area-under-curve abundance of the three parent drugs in pre- and post-ETI samples.

576


577 **Fig. 5.** *Mmvec analysis of sputum microbiomes and metabolomes from pwCF.* a) Biplot of the
578 metabolite and microbe vector associations. Each diamond represents a metabolite (only metabolites
579 annotated within the GNPS library are shown) and they are colored by their molecular family. The
580 vectors are the top 15 ASVs associated with the metabolomic dynamics and they are colored by
581 whether or not they are considered clinical pathogens or anaerobes. b) Conditional probability
582 distributions for the mean of all peptides identified in the dataset and their association with either
583 anaerobes (red) or pathogens (purple, p-value from DM T-test). c) Rank abundance of the conditional
584 probabilities of kynurenine with different anaerobes (red) and pathogens (purple) ASVs.







a)



b)

